StockData
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.91+0.10 (+5.52%)

Close on Nov 17, 2026Market cap $22.11MP/E –Yield –

TherapeuticsMD r&d expenses

Research and development expenses are spending on new products and technology.

TherapeuticsMD's R&D Expenses for the twelve months ending Sep 30, 2022 was $5.51M, down 31.6% year over year. For fiscal 2021 it was $7.09M, down 32.1% from the year before. Over ten years it grew 52.1% a year on average. The highest annual figure on record is $72.04M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2021Dec 31, 2021$7.09M-32.1%
FY2020Dec 31, 2020$10.43M-47.3%
FY2019Dec 31, 2019$19.79M-27.5%
FY2018Dec 31, 2018$27.30M-19.4%
FY2017Dec 31, 2017$33.85M-37.2%
FY2016Dec 31, 2016$53.94M-25.1%
FY2015Dec 31, 2015$72.04M+66.7%
FY2014Dec 31, 2014$43.22M+218.9%
FY2013Dec 31, 2013$13.55M+201.7%
FY2012Dec 31, 2012$4.49M+4089.0%
FY2011Dec 31, 2011$107.24K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2022Sep 30, 2022$1.11M-30.7%
Q2 FY2022Jun 30, 2022$1.58M-21.4%
Q1 FY2022Mar 31, 2022$1.40M-31.7%
Q4 FY2021Dec 31, 2021$1.42M-40.7%
Q3 FY2021Sep 30, 2021$1.61M-20.8%
Q2 FY2021Jun 30, 2021$2.01M-26.7%
Q1 FY2021Mar 31, 2021$2.05M-37.3%
Q4 FY2020Dec 31, 2020$2.39M-46.0%
Q3 FY2020Sep 30, 2020$2.03M-50.3%
Q2 FY2020Jun 30, 2020$2.74M-44.8%
Q1 FY2020Mar 31, 2020$3.27M-48.3%
Q4 FY2019Dec 31, 2019$4.43M-34.4%
Q3 FY2019Sep 30, 2019$4.08M-39.2%
Q2 FY2019Jun 30, 2019$4.96M-27.0%
Q1 FY2019Mar 31, 2019$6.32M-10.2%
Q4 FY2018Dec 31, 2018$6.75M-38.5%
Q3 FY2018Sep 30, 2018$6.71M+4.2%
Q2 FY2018Jun 30, 2018$6.80M-22.0%
Q1 FY2018Mar 31, 2018$7.04M-8.9%
Q4 FY2017Dec 31, 2017$10.97M+6.1%
Q3 FY2017Sep 30, 2017$6.44M-56.1%
Q2 FY2017Jun 30, 2017$8.72M–
Q1 FY2017Mar 31, 2017$7.72M–
Q4 FY2016Dec 31, 2016$10.34M–
Q3 FY2016Sep 30, 2016$14.66M–

More TherapeuticsMD figures

See a number that looks wrong?